| Revenue growth | 7% YoY for FY26; Q4 accelerated to 10%. |
|---|---|
| Margins | FY26 EBITDA margin at 21.2%; targeting steady annual expansion. |
| Demand visibility | Strong momentum in Top 10 brands contributing 58% of revenue. |
| Management confidence | High; citing sharper strategic execution and outperforming market growth. |
Growth
FY26 Revenue grew 6.9% to ₹2,872 Mn; Operational PAT rose 19% YoY to ₹446 Mn.
Outlook
Targeting 1.5x IPM growth and 100-150 bps annual margin improvement beyond FY27.
Risks
Regulatory changes, currency fluctuations, and competitive pressures in core therapy segments.
Earnings Call filed with NSE, NSE: JAGSNPHARM. Summary written with AI assistance from the document.
Jagsonpal Pharmaceuticals Ltd: key numbers
- Share price
- ₹242.29
- Market cap
- ₹1,598 Cr
- Revenue (annual)
- ₹287.2 Cr
- Net profit (annual)
- ₹43.08 Cr
- P/E (TTM)
- 35.1×Sector 50.4×
- Promoter holding
- 69.05%+1.16% QoQ
- FII holding
- 2.30%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jagsonpal Pharmaceuticals Ltd
All →Jagsonpal Pharmaceuticals Acquisition Worth ₹46.7 Cr
Jagsonpal Pharmaceuticals Ltd will acquire the Wellness Portfolio of Group Pharmaceuticals Ltd. The transaction involves a total consideration capped at ₹46.7 Crore.
- Value
- ₹46.70 Cr
Jagsonpal Pharmaceuticals Annual General Meeting
Jagsonpal Pharmaceuticals held its 47th Annual General Meeting on September 18, 2026. Shareholders transacted business including adoption of financial statements and director appointments.
Jagsonpal Pharmaceuticals Earnings Call Transcript: Key Takeaways
Jagsonpal reported a strong Q1FY27 with 9% revenue growth and 22% PAT growth, outperforming industry rates. The focus is on higher-margin specialty segments and integrating the Equitas acquisition to enter the hospital channel.
- Call
- Guides 18% growth
Jagsonpal Pharmaceuticals Investor Presentation: Key Takeaways
Jagsonpal Pharmaceuticals reported a strong start to FY27 with revenue up 9% YoY and PAT up 22%. The company completed the Aequitas acquisition to enter the hospital supplies segment.
Jagsonpal Pharmaceuticals Q1 FY27 Results: Net Profit ₹13.2 Cr, Up 22.2% YoY
Jagsonpal Pharmaceuticals Ltd reported revenue from operations of ₹82.2 Cr (+8.7% YoY) and net profit of ₹13.2 Cr (+22.2% YoY) for Q1 FY27.
- Key figure
- Net profit ₹13.2 Cr · +22.2% YoY
Jagsonpal Pharmaceuticals Earnings Call: Key Takeaways
Jagsonpal reported Q4 revenue of ₹64cr (up 10% YoY) and FY26 revenue of ₹287cr (up 7%). Strategy focuses on MR productivity and portfolio rejuvenation in Gynaecology and Dermatology.